English
GlaxoSmithKline Pharmaceuticals Q2 Results
- BSE: 500660
- NSE: GLAXO
- ISIN: INE159A01016
- Sector: Biotechnology & Drugs
BSE
2,477.90
-15.65 (-0.63%)
-15.65 (-0.63%)Volume1.79 K
Updated: Fri 14 Nov, 2025 | 15:56:48
NSE
2,479.40-15.10 (-0.61%)
-15.10 (-0.61%)Volume51.38 K
Updated: Fri 14 Nov, 2025 | 15:43:08
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹979.94 Cr.(-3.05%)
- Operating Profit₹318.30 Cr.(4.41%)
- Profit After Tax₹257.49 Cr.(1.98%)
- Operating Margin32.48%(7.70%)
Note: Comparison is on YoY basis
Quarterly - GlaxoSmithKline Pharmaceuticals Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 661.64 | 569.49 | 16.18% | 705.92 | -6.27% |
| Depreciation/ Amortization | 17.43 | 15.52 | 12.31% | 16.86 | 3.38% |
| Operating Income | 318.30 | 235.68 | 35.06% | 304.85 | 4.41% |
| Net Income | 257.49 | 205.01 | 25.60% | 252.50 | 1.98% |
| Other Operating Expenses Total | 150.63 | 113.69 | 32.49% | 153.86 | -2.10% |
| Net Income Before Taxes | 354.00 | 278.98 | 26.89% | 343.81 | 2.96% |
| Total Revenue | 979.94 | 805.17 | 21.71% | 1,010.77 | -3.05% |
| Selling/ General/ Admin Expenses Total | 138.05 | 152.57 | -9.52% | 150.71 | -8.40% |
| Diluted Normalized EPS | 15.09 | 12.10 | 24.68% | 14.47 | 4.26% |